Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2985415 | 1.00 | MLYCD (0.36) | MLYCDAR | |
| SCHEMBL2991724 | 1.00 | MLYCD (0.36) | MLYCDAR | |
| Thiophene SCHEMBL2988236 | 0.91 | MLYCD (0.32) | MLYCD | |
| SCHEMBL14037127 | 0.81 | MLYCD (0.37) | MLYCDAR | |
| SCHEMBL2981822 | 0.80 | MLYCD (0.34) | MLYCD | |
| SCHEMBL2983613 | 0.80 | MLYCD (0.34) | MLYCD | |
| SCHEMBL1599140 | 0.79 | SMN1; SMN2 (0.37) | MLYCD | |
| SCHEMBL2988611 | 0.79 | PSEN1 (0.35) | MLYCD | |
| SCHEMBL2991970 | 0.78 | MLYCD (0.34) | MLYCD | |
| SCHEMBL2979547 | 0.78 | MLYCD (0.34) | MLYCD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130226549-A1 | STRUCTURE-BASED FRAGMENT HOPPING FOR LEAD OPTIMIZATION AND IMPROVEMENT IN SYNTHETIC ACCESSIBILITY | TSENG, YUFENG J. (TW) | 2013-08-29 | — | — | US | disclosed |
| US-20130005721-A1 | INDOLIZINE INHIBITORS OF 5-LIPOXYGENASE | PANMIRA PHARMACEUTICALS, LLC (US) | 2013-01-03 | — | — | US | disclosed |
| US-20130005721-A1 | INDOLIZINE INHIBITORS OF 5-LIPOXYGENASE | PANMIRA PHARMACEUTICALS, LLC (US) | 2013-01-03 | — | — | US | disclosed |
| US-20130005721-A1 | INDOLIZINE INHIBITORS OF 5-LIPOXYGENASE | PANMIRA PHARMACEUTICALS, LLC (US) | 2013-01-03 | — | — | US | disclosed |
| EP-2480547-A2 | INDOLIZINE INHIBITORS OF 5-LIPOXYGENASE | Panmira Pharmaceuticals, LLC (US) | 2012-08-01 | — | — | EP | disclosed |
| US-20110112106-A1 | TRICYCLIC INHIBITORS OF 5-LIPOXYGENASE | AMIRA PHARMACEUTICALS, INC. (US) | 2011-05-12 | — | — | US | disclosed |
| US-7919621-B2 | Tricyclic inhibitors of 5-lipoxygenase | AMIRA PHARMACEUTICALS, INC. (US) | 2011-04-05 | — | — | US | disclosed |
| WO-2011038086-A2 | INDOLIZINE INHIBITORS OF 5-LIPOXYGENASE | AMIRA PHARMACEUTICALS, INC. (US) | 2011-03-31 | — | — | WO | disclosed |
| WO-2011038086-A2 | INDOLIZINE INHIBITORS OF 5-LIPOXYGENASE | AMIRA PHARMACEUTICALS, INC. (US) | 2011-03-31 | — | — | WO | disclosed |
| US-20100137371-A1 | Novel Pharmaceutical Compounds | MERCK FROSST CANADA LTD. (CA) | 2010-06-03 | — | — | US | disclosed |
| US-20100137371-A1 | Novel Pharmaceutical Compounds | MERCK FROSST CANADA LTD. (CA) | 2010-06-03 | — | — | US | disclosed |
| US-7439260-B2 | 7-(1,3-thiazol-2-YL)thio-coumarin derivatives and their use as leukotriene biosynthesis inhibitors | MERCK FORSST CANADA & CO. (CA) | 2008-10-21 | — | — | US | disclosed |
| US-7439260-B2 | 7-(1,3-thiazol-2-YL)thio-coumarin derivatives and their use as leukotriene biosynthesis inhibitors | MERCK FORSST CANADA & CO. (CA) | 2008-10-21 | — | — | US | disclosed |
| US-7439260-B2 | 7-(1,3-thiazol-2-YL)thio-coumarin derivatives and their use as leukotriene biosynthesis inhibitors | MERCK FORSST CANADA & CO. (CA) | 2008-10-21 | — | — | US | disclosed |
| EP-1978966-A2 | TRICYCLIC INHIBITORS OF 5-LIPOXYGENASE | Amira Pharmaceuticals, Inc. (US) | 2008-10-15 | — | — | EP | disclosed |
| WO-2007087250-A2 | TRICYCLIC INHIBITORS OF 5-LIPOXYGENASE | AMIRA PHARMACEUTICALS, INC. (US) | 2007-08-02 | — | — | WO | disclosed |
| US-20070173508-A1 | TRICYCLIC INHIBITORS OF 5-LIPOXYGENASE | AMIRA PHARMACEUTICALS, INC. (US) | 2007-07-26 | — | — | US | disclosed |
| US-20060116406-A1 | 7-(1,3-thiazol-2-yl)thio!-coumarin derivatives and their use as leukotriene biosynthesis inhibitors | GAREAU YVES | 2006-06-01 | — | — | US | disclosed |
| EP-1636222-A1 | 7-[(1,3-THIAZOL-2-YL)THIO]-COUMARIN DERIVATIVES AND THEIR USE AS LEUKOTRIENE BIOSYNTHESIS INHIBITORS | Merck Frosst Canada Ltd. (CA) | 2006-03-22 | — | — | EP | disclosed |
| WO-2004108720-A1 | 7- (1, 3-THIAZOL-2-YL)THIO!-COUMARIN DERIVATIVES AND THEIR USE AS LEUKOTRIENE BIOSYNTHESIS INHIBITORS | MERCK FROSST CANADA LTD. (CA) | 2004-12-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130005721-A1 | INDOLIZINE INHIBITORS OF 5-LIPOXYGENASE | ALOX5, ALOX15, ALOX15B | MLYCD 785/4885AR 3852/4885 |
| US-20070173508-A1 | TRICYCLIC INHIBITORS OF 5-LIPOXYGENASE | ALOX5, ALOX15, ALOX15B | MLYCD 470/4885AR 4632/4885 |
| US-20110112106-A1 | TRICYCLIC INHIBITORS OF 5-LIPOXYGENASE | ALOX5, ALOX15, ALOX15B | MLYCD 470/4885AR 4632/4885 |
| US-20060116406-A1 | 7-(1,3-thiazol-2-yl)thio!-coumarin derivatives and their use as leukotriene biosynthesis inhibitors | LTC4S, LTA4H, CYSLTR1 | MLYCD 2142/4885AR 3933/4885 |
| US-20100137371-A1 | Novel Pharmaceutical Compounds | LTC4S, LTA4H, LTB4R2 | MLYCD 2597/4885AR 3819/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.